Merck KGaA Bags Exclusive Rights To Develop, Sell Debiopharm’s Xevinapant
The IAP antagonist Is In Phase III Trials For Head And Neck Cancer
Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.
You may also be interested in...
After doing a number of healthcare deals in 2021, it looks as though Merck KGaA will keep M&A activity to a minimum for the division this year, focusing instead on advancing its own promising candidates for cancer, multiple sclerosis and lupus.
Belén Garijo, the German group's CEO, has told analysts she considers targeted smaller to medium-sized acquisitions to be more likely than major transformational deals but said that "we are always open to something bolder."
Less than two months after bintrafusp failed to beat Merck & Co's blockbuster Keytruda in a Phase III NSCLC trial, Merck KGaA's bispecific fusion protein partnered with GSK has disappointed in a mid-stage study for biliary tract cancer.